DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Fundación Jiménez Díaz
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Fundación Jiménez Díaz (7)
2023
-
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Investigational New Drugs, Vol. 41, Núm. 5, pp. 677-687
2022
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
European Journal of Cancer, Vol. 172, pp. 340-348
-
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
ESMO Open, Vol. 7, Núm. 5
2018
-
Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
2017
-
BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer
Clinical Cancer Research, Vol. 23, Núm. 23, pp. 7388-7399
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7